Compass Pathways Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Highlights

Contributed by: Business Wire

Logo

Tags

Research

Mental Health

FDA

Clinical Trials

Biotechnology

Alternative Medicine

Pharmaceutical

Health

Science

Other Science

Compass Pathfinder Limited

More Like This

Compass Pathways Announces Second Quarter 2025 Financial Results and Business Highlights

Compass Pathways Announces Fourth Quarter and Full-Year 2024 Financial Results and Business Highlights

Compass Pathways Announces Third Quarter 2025 Financial Results and Business Highlights Including Acceleration of Commercial Launch Plans by 9-12 Months

Compass Pathways Announces Third Quarter 2024 Financial Results and Business Updates

Compass Pathways Announces First Quarter 2025 Financial Results and Business Highlights

Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression

Compass Pathways Announces Completion of Recruitment for the Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression

Compass Pathways Announces Dosing Complete for All Participants in Part A of Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression